Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis-Reference-Cited by-同舟云学术

Effect of Dupilumab in Korean Patients With Uncontrolled Moderate-to-Severe Asthma: A LIBERTY ASTHMA QUEST Sub-analysis

Published:2022 Issue:2 Volume:14 Page:182
ISSN:2092-7355
Container-title:Allergy, Asthma & Immunology Research
language:en
Short-container-title:Allergy Asthma Immunol Res

Author:

Rhee Chin Kook¹^ORCID,Park Jung-Won²^ORCID,Park Heung-Woo³^ORCID,Cho You Sook⁴^ORCID

Affiliation:

1. Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.

2. Division of Allergy and Immunology, Department of Internal Medicine, Institute of Allergy, Yonsei University College of Medicine, Seoul, Korea.

3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea; Institute of Allergy and Clinical Immunology, Seoul National University Medical Research Center, Seoul, Korea.

4. Division of Allergy and Clinical Immunology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.

Publisher

The Korean Academy of Asthma, Allergy and Clinical Immunology and The Korean Academy of Pediatric Al

Subject

Pulmonary and Respiratory Medicine,Immunology,Immunology and Allergy

Link

https://e-aair.org/pdf/10.4168/aair.2022.14.2.182

Reference19 articles.

1. High Prevalence of Asthma in Elderly Women: Findings From a Korean National Health Database and Adult Asthma Cohort

2. Biological treatments for severe asthma

3. Dupilumab in the Treatment of Moderate to Severe Asthma: An Evidence-Based Review

4. U.S. Food & Drug Administration. Dupixent prescribing information [Internet]. Silver Spring (MD). U.S. Food & Drug Administration. 2017. cited 2020 Nov 3. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761055s014lbl.pdf

5. European Medicines Agency. Prescribing information. Dupixent [Internet]. Amsterdam. European Medicines Agency. 2017. cited 2021 Sep 14. Available from: https://www.ema.europa.eu/en/documents/product-information/dupixent-epar-product-information_en.pdf

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost-effectiveness analysis of dupilumab among patients with uncontrolled severe asthma using LIBERTY ASTHMA QUEST Korean data;Health Economics Review;2024-08-26

2. Real-World Effectiveness of Biologics in Patients With Severe Asthma: Analysis of the KoSAR;Allergy, Asthma & Immunology Research;2024

3. Long-term Safety and Efficacy of Dupilumab in Patients With Uncontrolled, Moderate-to-Severe Asthma Recruited From Korean Centers: A Subgroup Analysis of the Phase 3 LIBERTY ASTHMA TRAVERSE Trial;Allergy, Asthma & Immunology Research;2024

4. Long-term efficacy of anti-IL-4 receptor antibody in a patient with aspirin-exacerbated respiratory disease and IgG4-related disease;Allergy, Asthma & Clinical Immunology;2023-08-05

5. Long-term Efficacy of Anti-IL-4 Receptor Antibody in a Patient With Aspirin-Exacerbated Respiratory Disease and IgG4-Related Disease;2023-05-17